Ability to switch suppliers likely to be key question in EC review of Novo Nordisk/Catalent deal

The European Commission (EC) will review how easy it would be for Catalent’s existing clients to switch to alternative contract drug manufacturers, as part of its antitrust probe of Novo Nordisk's deal with Catalent, a Brussels-based antitrust lawyer...

To read the full article and get unlimited access to our exclusive coverage

 

Already a Member? Log in Below.
error: Content is protected !!
Scroll to Top
Scroll to Top

Valeria Camerino

Valeria is a seasoned business and financial journalist with fifteen years of industry experience.

Before launching Equity Report in October 2022, Valeria was European Editor for US-based financial news service CTFN, where she spent seven years reporting on event-driven situations, breaking news stories on complex financial and regulatory issues across several jurisdictions, from Europe and Africa to China, India, Brazil, and Australia.

Prior to that, she was Senior Reporter at TelecomFinance, Middle East correspondent, and later Southern Europe correspondent at Mergermarket (currently ION), and held a number of editorial positions with Dubai and London-based b2b publications.

She holds a BA (Hons) in Languages and Public Relations from Leeds Beckett University and an MA in International Journalism from University of Central Lancashire.